title: Erythropoietin-receptor agonists in critically ill patients: a meta-analysis of randomized controlled trials.
abstract: BACKGROUND
  Anemia and the need for red blood cell transfusions are common among patients admitted to intensive care units. Erythropoietin has been used to decrease the need for transfusions; however, its ability to improve clinical outcomes is unknown. We evaluated the effect of erythropoietin-receptor agonists on clinically important outcomes, including mortality, length of stay in hospital or intensive care unit, ventilator use, transfusion requirements and major adverse events.
  
  
  METHODS
  To identify relevant studies, we searched electronic databases covering 1950 to 2007 (MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials and the Scopus database). We also searched conference proceedings and grey literature sources. We selected all randomized controlled trials involving critically ill patients that compared an erythropoietin-receptor agonist with a placebo or no intervention. No language restrictions were considered. Data were extracted using a standardized extraction template. We used a fixed effects model to calculate all summary measures of treatment effects.
  
  
  RESULTS
  Of 673 identified records, 9 studies that investigated erythropoietin alpha met the eligibility criteria and were included in our analysis. Erythropoietin, compared with placebo or no intervention, had no statistically significant effect on overall mortality (odds ratio [OR] 0.86, 95% confidence interval [CI] 0.71-1.05, I2 = 0%). The treatment and control groups did not differ in the length of stay in hospital or intensive care unit, or in the duration of mechanical ventilation, in the 3 studies that reported these outcomes. Erythropoietin, compared with placebo, significantly reduced the odds of a patient receiving at least 1 transfusion (OR 0.73, 95% CI 0.64-0.84, I2 = 54.7%). The mean number of units of blood transfused per patient was decreased by 0.41 units in the erythropoietin group (95% CI 0.10-0.74, I2 = 79.2%). Most of the included studies were performed before the widespread adoption of a restrictive transfusion strategy. Only 1 study provided detailed reports of adverse events, and none of the studies systematically evaluated all patients for venous thromboembolism.
  
  
  CONCLUSIONS
  At this time, we do not recommend the routine use of erythropoietin-receptor agonists in critically ill patients. The reduction in red blood cell transfusions per patient was very small, and there is insufficient evidence to determine whether this intervention results in clinically important benefits with acceptable risks.
authors.affiliation: Department of Epidemiology and Community Medicine, University of Ottawa, and the Ottawa Health Research Institute, Ottawa, Ont. ryan@zarychanski.com
authors.forename: Ryan
authors.initials: R
authors.lastname: Zarychanski
authors.forename: Alexis F
authors.initials: AF
authors.lastname: Turgeon
authors.forename: Lauralyn
authors.initials: L
authors.lastname: McIntyre
authors.forename: Dean A
authors.initials: DA
authors.lastname: Fergusson
mesh_terms: D000740:Anemia / Q000188:drug therapy* / Q000628:therapy; D016638:Critical Illness; D000068817:Epoetin Alfa; D017707:Erythrocyte Transfusion; D004921:Erythropoietin / Q000627:therapeutic use*; D006397:Hematinics / Q000627:therapeutic use*; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D017467:Receptors, Erythropoietin / Q000819:agonists*; D011994:Recombinant Proteins